Global Oncology Generic Injectable Drugs Market Insights and Forecast to 2028

Generic drugs are essential in oncology because some anticancer drugs are only available as generics.
Market Analysis and Insights: Global Oncology Generic Injectable Drugs Market
Due to the COVID-19 pandemic, the global Oncology Generic Injectable Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Large Molecule Drugs accounting for % of the Oncology Generic Injectable Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period.
China Oncology Generic Injectable Drugs market size is valued at US$ million in 2021, while the US and Europe Oncology Generic Injectable Drugs are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Oncology Generic Injectable Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Oncology Generic Injectable Drugs include Teva Pharmaceutical, Pfizer, AstraZeneca, Roche, Eli Lilly, GlaxoSmithKline, Novartis, Mylan and Natco Pharma. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Oncology Generic Injectable Drugs Scope and Segment
Oncology Generic Injectable Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Oncology Generic Injectable Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Large Molecule Drugs
Small Molecule Drugs
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Company
Teva Pharmaceutical
Pfizer
AstraZeneca
Roche
Eli Lilly
GlaxoSmithKline
Novartis
Mylan
Natco Pharma
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E